Strategy
SCYNEXIS Wins a BARDA Contract Worth Up to $214 Million for Its Antifungal SCY-247
The base award is about $18.5 million; the rest depends on options the government may exercise across a term of up to 10 years.
AF
By Anna Ferreira
Sep 28, 2026 · 5 min read
SCYNEXIS said Monday it has been awarded a contract from the Biomedical Advanced Research and Development Authority providing up to roughly $214 million in non-dilutive funding to develop SCY-247, an investigational antifungal.
Discussion (0)
Sign in to join the discussion.
Loading comments…
AF
Anna Ferreira
Senior Correspondent, Corporate Strategy
Anna Ferreira writes for Corporate Insider Inc.